In vivoeffect of interferon-β 1a on interleukin-12 and TGF-β₁cytokines in patients with relapsing-remitting multiple sclerosis

Abstract

We have studied in vivo effect of interferon-beta 1a (IFN-beta 1a) (6 MIU once weekly i.m.) on interleukin-12 (IL-12) and transforming growth factor-beta(1) (TGF-beta(1)) serum levels during 6 months of therapy in group of 20 patients with relapsing-remitting multiple sclerosis (MS). IL-12 and TGF-beta(1) concentrations were measured by enzyme linked immunoabsorbent assay (ELISA). There was a significant increase of IL-12 levels in MS patients in comparison with control group, suggesting a role of this cytokine in immunity of MS. We have also found a significant increase of TGF-beta(1) levels after 6 months of therapy with IFN-beta 1a, however, there was no in vivo effect of the therapy on IL-12 levels. The results suggest that IFN-beta 1a may exert its action through up- regulation and increase secretion of TGF-beta(1).

Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis

“…Although increased levels of IL-10 were detected after IFNβ treatment, TGFβ production was minimal. Previous studies have demonstrated that TGFβ was decreased in the peripheral blood mononuclear cells of MS patients with the relapsing-remitting form of MS and it increased after therapy with IFNβ [32], a finding confirmed by the results reported here. Similar results were also observed with another therapeutic approach to the treatment of MS, such as oral tolerization with bovine myelin, which also increased the frequency of TGFβ secreting T cell lines in response to neuroantigen (MBP and PLP) [44].…”

“…No reduction in IL-12 level after IFNβ treatment was found here. The lack of in vivo effect of the IFNβ therapy on IL-12 levels was also previously demonstrated [32]. On the other hand, it has been clearly demonstrated that the level of TNFα decreased significantly in the group of MS patients treated with IFNβ, with or without LPS stimulation, a beneficial effect that has previously reported [33][34][35][36].…”

Does Lipoic Acid Consumption Affect the Cytokine Profile in Multiple Sclerosis Patients: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

“…Inflammatory cytokines influenced the CNS via transmission from the blood-brain barrier by the assistance of the high levels of adhesion molecules as well as augmentation of the proteolytic enzymes function. MMP, one of the important proteases, plays an important role in the pathology of MS [33,34]. LA consumption caused reduced MMP-9 function in the vessels of muscle cells [33].…”

“…There are few studies available regarding the roles of TGF-β on the pathogenesis of MS and most of them assessed the effect of INF-β on TGF-β changes [34]. It appears that LA consumption does indeed have a significant impact on cytokines among MS patients.…”

Resurgence of vitamin D: Old wine in new bottle

“…142 Elevated transforming growth factor b1 levels have been associated with the stable phase of multiple sclerosis, whereas reduced levels have been associated with relapsing-remitting multiple sclerosis. 143,144 12.4. VD and type I diabetes mellitus 1,25(OH)2D acts as an immune modulator, reducing cytokine production and lymphocyte proliferation, which have been implicated in the destruction of insulin-secreting b cells in the pancreas and the development of type 1diabetes mellitus.…”